Petr P.
- Country
- Czechia
- Department
- Interni hematologicka klinika
Research Overview
- Phase 3 Randomized Study of JNJ‑79635322 Versus Teclistamab in Relapsed or Refractory Multiple Myeloma After 1–3 Prior Lines Including Anti‑CD38 Antibody and Lenalidomide
- Phase 3 Randomized Trial of Talquetamab, Daratumumab, and Pomalidomide Combinations in Relapsed/Refractory Multiple Myeloma Post-One Therapy Line
- Phase 3 Open-Label Study of Elranatamab vs. Elotuzumab, Pomalidomide, Dexamethasone, or Carfilzomib in Relapsed/Refractory Multiple Myeloma Post Anti-CD38 Therapy
Data & Insights
Has run more than one trial at 108 of 251 partner sites.
Specializations
Multiple Myeloma Research
The investigator specializes in both newly diagnosed multiple myeloma (NDMM) and relapsed/refractory multiple myeloma (RRMM) treatment approaches.
- Novel Therapeutic Combinations
- Post-transplant Maintenance Therapy
- Antibody-based Treatments
Focuses on innovative treatment strategies for patients who are ineligible for stem cell transplantation.
Immunotherapy Applications
Explores advanced immunotherapeutic approaches in hematologic malignancies, with particular emphasis on monoclonal antibody therapies.
- Anti-CD38 Directed Therapies
- Antibody-Drug Conjugates
- Combination Immunotherapy
Investigates novel antibody-based treatment combinations to enhance therapeutic outcomes.
Treatment Optimization
Specializes in developing optimized treatment regimens for various stages of multiple myeloma.
- Drug Scheduling Strategies
- Dosing Optimization
- Safety Profile Enhancement
Works on improving therapeutic efficacy while maintaining manageable toxicity profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.